Up‐regulated expression of ADAM17 in human colon carcinoma: co‐expression with EGFR in neoplastic and endothelial cells

• DOI: 10.1002/path.1814
• Publication Date: 2005-07-22T15:41:01Z
• Authors: Frédérique Blanch...; Anne Jarry; Damien Masson; Kalyane Bach‐Ngohou; Jacques Paineau; Marc G Denis; Christian L Laboisse; Jean‐François Mos...
• Keywords: CISH; Neoplastic transformation

Abstract The ADAM17 metalloproteinase (a disintegrin and metalloprotease 17) controls epidermal growth factor receptor (EGFR) activation through regulated shedding of EGFR ligands. With the advent new therapeutic options targeting signalling in colon carcinoma, it was decided to determine status relation clinico‐pathological parameters status. To this end, a series 39 carcinomas were analysed. Immunohistochemistry immunofluorescence used localize ADAM17, EGFR, activated forms EGFR. form assessed primary cancers cell lines by immunoblotting. mRNA levels quantitative RT‐PCR. Chromogenic situ hybridization (CISH) quantify HER1 gene. strongly expressed all tumours, both neoplastic endothelial cells. It as pro‐ an active tumours colonic cancer lines. up‐regulated 90% relative paired normal mucosa, whatever tumour grade or stage. When present, co‐expressed with carcinomas, although at variable level among cells, overexpressed 77% compared mucosa. One case showed high‐level amplification . In conclusion, study is first demonstration that human stage differentiation expression. Its co‐expression suggests role for angiogenesis. Copyright © 2005 Pathological Society Great Britain Ireland. Published John Wiley & Sons, Ltd.